Upstream Bio Inc.: Clinical Trials

6 trials sponsored by Upstream Bio Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Completed 2
Phase 12Completed 2

Follow Upstream Bio Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Verekitug, Placebo - Chronic Obstructive Pulmonary Disease
Phase 2Active not recruitingUpstream Bio Inc.6662025-07-022026-07-20
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Verekitug, Placebo - Severe Asthma
Phase 2Active not recruitingUpstream Bio Inc.3962025-05-212026-05-14
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
Verekitug (UPB-101), Placebo - Severe Asthma
Phase 2CompletedUpstream Bio Inc.4792024-02-272026-05-01
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
Verekitug (UPB-101), Placebo - Chronic Rhinosinusitis With Nasal Polyps
Phase 2CompletedUpstream Bio Inc.812023-12-182026-09-18
Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults
UPB-101 - Healthy
Phase 1CompletedUpstream Bio Inc.322022-12-052024-09-03
Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics
UPB-101, Placebo - Asthma
Phase 1CompletedUpstream Bio Inc.322022-07-082025-01-03

Conditions studied

Asthma (3)  ·  Respiratory Tract Diseases (3)  ·  Bronchial Diseases (2)  ·  Lung Diseases (2)  ·  Bronchitis, Chronic (1)  ·  Emphysema (1)  ·  Nasal Polyps (1)  ·  Nose Diseases (1)  ·  Otorhinolaryngologic Diseases (1)  ·  Paranasal Sinus Diseases (1)  ·  Pneumonia (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Sinusitis (1)

Interventions

Saline Solution (1)

Countries

United Kingdom (5)  ·  Czechia (4)  ·  Germany (4)  ·  Poland (4)  ·  Spain (4)  ·  United States (4)  ·  Argentina (3)  ·  Bulgaria (3)  ·  Chile (3)  ·  South Korea (3)  ·  Ukraine (3)  ·  Canada (2)  ·  Italy (2)  ·  Japan (2)  ·  South Africa (2)

Top investigators

Justin Salciccioli, MD (3)  ·  Chaim Brickman (1)  ·  Sumathi Sivapalasingam, MD (1)

Results publications

PMID 39393433

NIH funding

2023 (2), 2025 (1)